Medicamen Biotech Board of Directors
Get the latest insights into the leadership at Medicamen Biotech. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Rahul Bishnoi | Chairman |
| Vimal Kumar Shrawat | Non Independent & Non Executive Director |
| Ashwani Kumar Sharma | Non Independent & Non Executive Director |
| Suresh Kumar Singh | Non Independent & Non Executive Director |
| Sanjay Bansal | Non Independent & Non Executive Director |
| Ravi Kumar Bansal | Non Executive Independent Director |
| Sumita Dwivedi | Non Executive Independent Director |
| Sham Goel | Non Executive Independent Director |
| Parul Choudhary | Company Secretary & Compliance Officer |
| Shaival Saurabh | Non Executive Independent Director |
Medicamen Biotech FAQs
The board at Medicamen Biotech consists of experienced professionals, including Rahul Bishnoi, Vimal Kumar Shrawat, and others, overseeing the company’s strategic and corporate governance.
Directors at Medicamen Biotech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Rahul Bishnoi is the current chairman at Medicamen Biotech.
Executive directors at Medicamen Biotech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Medicamen Biotech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Medicamen Biotech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
Medicamen Biotech Associated Pages
